Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Depreciation & Amortization (CF) (2016 - 2025)

Rocket Pharmaceuticals' Depreciation & Amortization (CF) history spans 10 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 7.9% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $8.9 million, up 22.85%, while the annual FY2025 figure was $8.9 million, 22.85% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $1.7 million at Rocket Pharmaceuticals, down from $2.7 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.7 million in Q3 2025 and bottomed at -$2.1 million in Q4 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $1.2 million (2023), against an average of $1.3 million.
  • The largest annual shift saw Depreciation & Amortization (CF) soared 606.0% in 2021 before it crashed 295.0% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.1 million in 2021, then plummeted by 295.0% to -$2.1 million in 2022, then surged by 167.54% to $1.4 million in 2023, then soared by 30.52% to $1.8 million in 2024, then fell by 7.9% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Depreciation & Amortization (CF) are $1.7 million (Q4 2025), $2.7 million (Q3 2025), and $2.0 million (Q2 2025).